Caribou Biosciences (CRBU)
NASDAQ:CRBU
Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$2.20
-$0.16(-8.56%)
At close: 4:00 PM EST
$2.20
-$0.16(-8.56%)
Day’s Range― - ―
52-Week Range$1.22 - $3.54
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.20M
Market Cap
$166.62M
Enterprise Value$177.55M
Total Cash (Recent Filing)$117.63M
Total Debt (Recent Filing)$26.95M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Aug 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding99,180,570
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue15.85
Enterprise Value/Gross Profit19.18
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$8.75Price Target Upside297.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$23.61M
Bulls Say, Bears Say
Bulls Say
Proprietary CRISPR Platform & Allogeneic FocusCaribou’s chRDNA-guided CRISPR platform and explicit focus on allogeneic, off-the-shelf cell therapies represent a durable business model advantage: potential for scalable manufacturing, lower per-patient cost vs autologous CAR-T, and recurring licensing/collaboration revenue streams that support long-term commercial optionality and partner interest.
Regulatory Support: RMAT Designation For CB-011RMAT status for CB-011 signals regulatory recognition of meaningful clinical potential and an accelerated, guidance-oriented review pathway. This materially strengthens long-term development prospects, may shorten time to approval, and increases partner and investor confidence in the program's strategic value.
Robust Early Clinical Efficacy SignalsConsistently high response and MRD-negativity rates across CaMMouflage and ANTLER early cohorts provide durable clinical proof-of-concept for Caribou’s allogeneic CAR-T candidates. These outcomes underpin plans for pivotal trials, enhance commercial potential, and reduce scientific risk relative to earlier-stage programs.
Bears Say
Persistent Large Operating LossesSustained large operating losses reflect a cost base far exceeding current revenues. Over months this erodes capital, forces reliance on external financing, and can trigger dilutive raises or program cuts, constraining strategic flexibility and extending the timeline to self-sustaining operations.
High Cash Burn And Negative Free Cash FlowDeep negative operating and free cash flow indicate ongoing financing needs. Persistent cash burn increases refinancing risk and the probability of equity dilution, limiting the company’s ability to fund concurrent programs, scale manufacturing, or absorb setbacks without external capital.
Revenue Decline And Shrinking Equity CushionMaterial revenue step-down and a sharply contracted equity base reduce financial resilience. With lower recurring revenue and diminished equity cushion, the firm is more exposed to clinical setbacks or funding delays, raising the likelihood of financing pressure or strategic trade-offs over the medium term.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.22 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $166.62M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Aug 11, 2026 which is in 44 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.05.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 99,180,570 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 3.191%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (297.73% Upside)
$8.75 (297.73% Upside)
Hedge Fund Trend
Decreased
By 68.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
-100.13%
Trailing 12-Months
Asset Growth
-45.55%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.75
▲(297.73% Upside)
Technical Analysis
Sangamo Therapeutics
―
Cellectis SA
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
4.66% Insiders
5.81% Mutual Funds
12.45% Other Institutional Investors
69.65% Public Companies and
Individual Investors